PHILADELPHIA, April 08, 2022 (Globe NEWSWIRE) — AnPac Bio-Professional medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China targeted on early cancer screening and detection, declared that Dr. Aidong Chen has joined the Firm as its board director, Main Government Officer and Chairman of the Board of Directors. Dr. Aidong Chen has been a training physician and researcher for more than 10 decades. He has been given about 20 world wide patents on his do the job and released 91 papers above his occupation. Dr. Chen has been affiliated with many main hospitals, including Yijishan Hospital, and Nanjing Healthcare University. He has replaced Dr. Chris Yu, Company’s founder, who resigned as board director, CEO and Chairman of the Board of the Enterprise. As head of China functions of the Corporation, Dr. Yu will continue being with the Enterprise in a senior management job to concentrate on rising company in China.
The Company will also be introducing Sheng “Dorothy” Liu to the Board of Administrators, who will be changing Mr. Chao Feng. Ms. Liu is at this time the CEO of Zhongjintai Undertaking Cash (Shenzhen) Co., Ltd., a enterprise capital business in Shenzhen. She has worked in finance and consulting, such as in personal equity, for practically 10 yrs. Ms. Liu will be an impartial director and will also provide as a member of the Payment Committee and Chairperson of the Nominating Committee.
About AnPac Bio
AnPac Bio is a biotechnology business centered on early most cancers screening and detection, with 150 issued patents as of September 30, 2021. With two licensed clinical laboratories in China and a single CLIA and CAP accredited medical laboratory in the United States, AnPac Bio performs a suite of cancer screening and detection exams, which includes CDA (Most cancers Differentiation Assessment), bio-chemical, immunological, and genomics checks. According to a report by Frost & Sullivan, AnPac Bio rated initial globally in multi-most cancers screening and detection test sample quantity (accumulative to January 2021). AnPac Bio’s CDA know-how platform has been demonstrated in retrospective validation studies to be ready to detect the danger of around 20 diverse most cancers forms with large sensitivity and specificity.
For additional details, be sure to visit: https://www.Anpacbio.com.
For trader and media inquiries, you should call:
Phil Case, Internet marketing and Trader Relations
Telephone: +1-267-810-6776 (US)
Email: [email protected]
Ascent Investor Relations LLC
Tina Xiao, President
Cell phone: +1-917-609-0333 (US)
Email: [email protected]
Safe Harbor Statement
This announcement is made up of forward-searching statements within the indicating of Area 27A of the Securities Act of 1933 and Section 21E of the Securities Trade Act of 1934. These ahead-on the lookout statements are created underneath the “safe harbor” provisions of the Non-public Securities Litigation Reform Act of 1995 and are relating to the Company’s foreseeable future money and operating general performance. The Firm has attempted to identify forward-hunting statements by terminologies which includes “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “target,” “aim,” “predict,” “outlook,” “seek,” “goal” “objective,” “assume,” “contemplate,” “continue,” “positioned,” “forecast,” “likely,” “may,” “could,” “might,” “will,” “should,” “approximately” or other phrases that convey uncertainty of potential gatherings or outcomes to establish these ahead-looking statements. These statements are dependent on recent expectations, assumptions and uncertainties involving judgments about, among the other issues, long run economic, competitive and market place disorders and foreseeable future company decisions, all of which are tricky or unattainable to forecast precisely and quite a few of which are further than the Company’s manage. These statements also require acknowledged and not known risks, uncertainties and other variables that may bring about the Company’s actual benefits to be materially distinct from those people expressed or implied by any ahead-on the lookout assertion. Recognized and unknown pitfalls, uncertainties and other variables consist of, but are not limited to, our capability to comply with Nasdaq Listing Policies, the implementation of our small business product and progress tactics trends and competitors in the most cancers screening and detection marketplace our anticipations concerning need for and sector acceptance of our cancer screening and detection exams and our capacity to grow our shopper foundation our capability to attain and keep intellectual residence protections for our CDA technological innovation and our ongoing investigation and progress to continue to keep tempo with engineering developments our skill to obtain and preserve regulatory approvals from the NMPA, the Fda and the suitable U.S. states and have our laboratories qualified or accredited by authorities which include the CLIA our upcoming enterprise development, economical ailment and benefits of operations and our skill to receive funding expense-effectively possible alterations of governing administration polices basic financial and business disorders in China and in other places our skill to employ the service of and retain important staff our marriage with our key enterprise companions and consumers and the period of the coronavirus outbreaks and their opportunity adverse affect on the financial ailments and fiscal marketplaces and our organization and monetary functionality, this sort of as ensuing from minimized commercial pursuits thanks to quarantines and journey limits instituted by China, the U.S. and quite a few other countries all around the world to consist of the unfold of the virus. Also, all forward-seeking statements are subject matter to the “Risk Factors” comprehensive from time to time in the Company’s most new Once-a-year Report on Variety 20-F and other filings with the U.S. Securities and Trade Commission. Mainly because of these and other hazards, uncertainties and assumptions, undue reliance must not be placed on these ahead-searching statements. In addition, these statements communicate only as of the day of this push launch and, except as may perhaps be necessary by law, the Enterprise undertakes no obligation to revise or update publicly any ahead-wanting statements for any purpose.